Purdue Pharma to be dissolved in opioid settlement

The End of Purdue Pharma

Purdue Pharma, the manufacturer of OxyContin, is slated to be dissolved by the end of the week as a comprehensive legal settlement takes effect. This settlement resolves thousands of lawsuits filed against the company for its role in the opioid crisis, which has claimed over 900,000 lives in the US since 1999.

Terms of the Settlement

As part of the deal, Purdue Pharma will admit to not having an effective program to prevent its powerful painkillers from being diverted to the black market. The company will also admit to paying doctors to prescribe the drugs and providing information to encourage more opioid prescriptions. The settlement includes $8.3 billion in forfeitures, fines, and penalties, although the company will only pay $225 million to the federal government.

Victims' Reactions

Many victims of the opioid crisis expressed frustration with the settlement, arguing that it does not provide them with real justice. Some asked the judge to reject the negotiated sentence, stating that it does not hold individual members of the Sackler family accountable. Over 54,000 people with personal injury claims voted to accept the settlement, while about 200 rejected it.

The Sackler Family's Role

Members of the Sackler family, who own Purdue Pharma, will contribute up to $7 billion over 15 years to fight the opioid crisis. Most of the funds will go to government entities. The settlement also shields family members from lawsuits over opioids for those who agree to the payments.

A New Era for Purdue Pharma

Under the settlement, Purdue Pharma will cease to exist and be replaced by Knoa Pharma, a new company with a board appointed by states and a mission to combat the opioid crisis. Millions of internal Purdue documents will be made public, and the Sackler family has agreed not to object to having their names removed from institutions they have supported.